Table 2.
Comparison of characteristics of patients with sepsis according to 28-day mortality.
| Characteristic | 28-day survivor (n = 53) | 28-day non-survivors (n = 23) | p-value |
|---|---|---|---|
| Age (years), median (IQR) | 70.0 (62–77) | 70.0 (66–78.5) | 0.519 |
| Gender, male, n (%) | 34/53 (64.2) | 12/23 (52.2) | 0.468 |
| BMI (kg/m2) | 22.5 (21.3–25.4) | 21.9 (19.2–25.6) | 0.288 |
| Site of infection, n (%) | |||
| Pulmonary | 20 (37.7) | 11 (47.8) | |
| Urinary tract | 21 (39.6) | 1 (4.3) | |
| Abdomena | 6 (11.3) | 8 (34.8) | 0.015 |
| Skin and soft tissue | 3 (5.7) | 1 (4.3) | |
| Othersb | 3 (5.7) | 2 (8.7) | |
| Charlson comorbidity index | 5 (3–6) | 6 (4–8) | 0.017 |
| Clinical parameters, n (%) | |||
| Positive blood culture | 24 (45.3) | 9 (39.1) | 0.806 |
| CRRT | 18 (33.9) | 17 (73.9) | 0.005 |
| Mechanical ventilation | 17 (32.1) | 13 (56.5) | 0.081 |
| Clinical severity score | |||
| APACHE II score | 21 (15–29) | 32 (22.5–39) | <0.001 |
| SOFA score | 8 (7–10) | 9 (8–12.5) | 0.120 |
| Laboratory parameters | |||
| Leukocytes (× 106/mL) | 12.74 (7.96–17.15) | 14.41 (6.51–19.89) | 0.779 |
| Platelets (× 106/mL) | 121 (80–187) | 172.5 (72.25–222) | 0.629 |
| CRP (mg/L) | 236.5 (131.9–298.8) | 164 (123.7–224.58) | 0.082 |
| Procalcitonin (ng/mL) | 25.22 (3.58–93) | 17.9 (2.11–35.67) | 0.216 |
| Lactate (mmol/L) | 2.6 (2–3.9) | 2.6 (1.75–8.6) | 0.311 |
| Albumin (g/dL) | 2.6 (2.1–2.8) | 2.3 (1.95–2.58) | 0.132 |
| Total Bilirubin (mg/dL) | 0.7 (0.4–1.2) | 0.6 (0.33–1.15) | 0.931 |
| BUN (mg/dL) | 38 (21.8–66.1) | 36.4 (26–61.3) | 0.870 |
| Creatinine (mg/dL) | 2.12 (1.25–3.15) | 2.65 (1.67–3.89) | 0.493 |
| Plasma EphA2 (pg/mL) | 475.88 (342.45–702.03) | 898.09 (647.15–1295.67) | <0.001 |
| Plasma Del-1 (pg/mL) | 32.68 (24.57–47.11) | 46.09 (25.19–58) | 0.193 |
Data are reported as medians (interquartile ranges [IQRs]) for continuous variables and numbers (percentages) for categorical variables. SIRS, systemic inflammatory response syndrome. BMI, body mass index; CRRT, continuous renal replacement therapy; APACHE II, Acute Physiology and Chronic Health Evaluation II; SOFA, Sequential Organ Failure Assessment; EphA2, erythropoietin-producing hepatocellular carcinoma A2; Del-1, developmental endothelial locus-1.
a
Abdomen: gastrointestinal and hepatobiliary infections, peritonitis.
b
Others: meningitis, spinal abscess, septic arthritis, primary unknown infection.